Atlas Principals, LLC Uni Qure N.V. Call Options Transaction History

Atlas Principals, LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2020 Feb 16, 2021	SELL	$35.35 - $50.67 $3 Million - $4.31 Million	-85,000 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$35.98 - $47.66 $1.35 Million - $1.79 Million	37,500 Added 78.95%	85,000 $3.13 Million
Q2 2020 Aug 14, 2020	BUY	$45.06 - $67.74 $946,260 - $1.42 Million	21,000 Added 79.25%	47,500 $2.14 Million
Q1 2020 May 15, 2020	BUY	$40.01 - $73.97 $1.06 Million - $1.96 Million	26,500 New	26,500 $1.26 Million

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Atlas Principals, LLC, based on Form 13F filings with the SEC.

Stay updated on Atlas Principals, LLC with notifications on news.